Allena Pharmaceuticals, Inc. (ALNA): Price and Financial Metrics


Allena Pharmaceuticals, Inc. (ALNA): $1.27

-0.03 (-2.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ALNA Stock Price Chart Interactive Chart >

Price chart for ALNA

ALNA Price/Volume Stats

Current price $1.27 52-week high $2.78
Prev. close $1.30 52-week low $1.02
Day low $1.23 Volume 836,300
Day high $1.30 Avg. volume 1,527,326
50-day MA $1.18 Dividend yield N/A
200-day MA $1.41 Market Cap 73.27M

Allena Pharmaceuticals, Inc. (ALNA) Company Bio


Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company’s lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is based in Newton, Massachusetts.


ALNA Latest News Stream


Event/Time News Detail
Loading, please wait...

ALNA Latest Social Stream


Loading social stream, please wait...

View Full ALNA Social Stream

Latest ALNA News From Around the Web

Below are the latest news stories about Allena Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNA as an investment opportunity.

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEWTON, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the granting of an inducement award to a new employee. In accordance with NASDAQ Listing Rule 5635(c)(4), the award was made as a material inducement to the employee’s entry into emplo

Yahoo | June 8, 2021

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney Disease

Webinar Scheduled for Wednesday, June 16th @ 12 pm EDTNEWTON, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it will host a key opinion leader (KOL) webinar focused on ALLN-346, a novel oral biologic currently in Phase 1 development for th

Yahoo | June 8, 2021

Moving Average Crossover Alert: Allena Pharmaceuticals (ALNA)

Allena Pharmaceuticals (ALNA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Yahoo | May 12, 2021

Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

-- Enrollment ongoing in Phase 3 URIROX-2 clinical trial of reloxaliase; interim analysis expected 2Q or 3Q 2022 ---- Enrolling healthy volunteers in Phase 1b MAD study of ALLN-346; initial data expected 3Q 2021 ---- On-track to initiate Phase 2a program for ALLN-346 in 3Q 2021; initial data expected 4Q 2021 ---- Company to host KOL webinar on the unmet need in gout and potential for ALLN-346 on June 16, 2021 -- NEWTON, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the first quarter ended March 31, 2021 and provided...

Yahoo | May 11, 2021

Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors

NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Mark J. Fitzpatrick to its board of directors. “Mark is an experienced industry executive, who has led financial strategy at biopharmaceutical companies across all stages of development,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “His extensive experience working with late-stage, rare disease companies will be particularly valuable as we continue to advance our ongoing Phase 3 URIROX-2 clinical trial and begin preparing...

Yahoo | April 7, 2021

Read More 'ALNA' Stories Here

ALNA Price Returns

1-mo 6.72%
3-mo -23.49%
6-mo 0.00%
1-year -25.29%
3-year -90.45%
5-year N/A
YTD -0.78%
2020 -53.11%
2019 -49.91%
2018 -45.83%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9289 seconds.